Skip to content

Study · Non-randomized trial · n = 16 · 2006

4 results

Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.

Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD

Journal of clinical pharmacology1 Oct 2006Cited by 46 (Europe PMC)

PMID16988207 (opens in a new tab)DOI10.1177/0091270006291622 (opens in a new tab)PepBankPUB-16988207
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy men, exenatide coadministration did not significantly change R-warfarin pharmacokinetics versus warfarin alone.

    In plain wordsExenatide did not significantly change how healthy men processed R-warfarin compared with warfarin alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeR-warfarin pharmacokinetics
    Study

    n = 16

    Comparator
    Warfarin alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide did not produce significant changes in R- or S-warfarin pharmacokinetics.
    2 context sentences
    Summary · context
    This open-label, 2-period, fixed-sequence study evaluated the influence of exenatide coadministration on the pharmacokinetics and pharmacodynamics of warfarin, a narrow therapeutic index drug, in healthy men (N = 16).
    Summary · context
    A single, 25-mg oral dose of warfarin, with a standardized breakfast, was administered alone in period 1 and concomitantly with 10 microg exenatide subcutaneous twice daily in period 2.
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy men, exenatide coadministration did not significantly change S-warfarin pharmacokinetics versus warfarin alone.

    In plain wordsExenatide did not significantly change how healthy men processed S-warfarin compared with warfarin alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeS-warfarin pharmacokinetics
    Study

    n = 16

    Comparator
    Warfarin alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide did not produce significant changes in R- or S-warfarin pharmacokinetics.
    2 context sentences
    Summary · context
    This open-label, 2-period, fixed-sequence study evaluated the influence of exenatide coadministration on the pharmacokinetics and pharmacodynamics of warfarin, a narrow therapeutic index drug, in healthy men (N = 16).
    Summary · context
    A single, 25-mg oral dose of warfarin, with a standardized breakfast, was administered alone in period 1 and concomitantly with 10 microg exenatide subcutaneous twice daily in period 2.
  3. 03HumanNon-randomized trialActivity measurement

    In healthy men, adding exenatide to warfarin slightly reduced INR-time area under the curve versus warfarin alone.

    In plain wordsAdding exenatide slightly reduced warfarin's blood-thinning response over time compared with warfarin alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseINR-time area under curve
    Study

    n = 16

    Comparator
    Warfarin alone
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Measurements

    INR-time AUC geometric mean ratio
    0.94 ratio
    exenatide coadministration versus warfarin alone

    Source sentences

    Summary
    Although there were minor reductions in warfarin anticoagulant effect, the ratios of geometric means for the area under the international normalized ratio (INR)-time curve from dosing until the time of the last measurable INR value or maximum-observed INR response being 0.94 (0.93-0.96) and 0.88 (0.…
    2 context sentences
    Summary · context
    This open-label, 2-period, fixed-sequence study evaluated the influence of exenatide coadministration on the pharmacokinetics and pharmacodynamics of warfarin, a narrow therapeutic index drug, in healthy men (N = 16).
    Summary · context
    A single, 25-mg oral dose of warfarin, with a standardized breakfast, was administered alone in period 1 and concomitantly with 10 microg exenatide subcutaneous twice daily in period 2.
  4. 04HumanNon-randomized trialActivity measurement

    In healthy men, adding exenatide to warfarin slightly reduced maximum INR response versus warfarin alone.

    In plain wordsAdding exenatide slightly reduced warfarin's maximum blood-thinning response compared with warfarin alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMaximum INR response
    Study

    n = 16

    Comparator
    Warfarin alone
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 microg twice daily · subcutaneousAs given in this study (human).

    Measurements

    Maximum INR geometric mean ratio
    0.88 ratio
    exenatide coadministration versus warfarin alone

    Source sentences

    Summary
    Although there were minor reductions in warfarin anticoagulant effect, the ratios of geometric means for the area under the international normalized ratio (INR)-time curve from dosing until the time of the last measurable INR value or maximum-observed INR response being 0.94 (0.93-0.96) and 0.88 (0.…
    2 context sentences
    Summary · context
    This open-label, 2-period, fixed-sequence study evaluated the influence of exenatide coadministration on the pharmacokinetics and pharmacodynamics of warfarin, a narrow therapeutic index drug, in healthy men (N = 16).
    Summary · context
    A single, 25-mg oral dose of warfarin, with a standardized breakfast, was administered alone in period 1 and concomitantly with 10 microg exenatide subcutaneous twice daily in period 2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.